Browsing Tag
MUIR-3
1 post
From rare disease to mass market: plozasiran gets FDA green light for severe hypertriglyceridemia review
Arrowhead’s plozasiran receives FDA Breakthrough Therapy status for severe hypertriglyceridemia. Learn what this means for trials, patients, and the RNAi market.
December 2, 2025